Human Growth Hormone (hGH) Market Size, Trends, Share, Growth | Report 2022-2030
The global Human Growth Hormone (hGH) market was estimated at USD 3,865.4 million in 2021 and it is expected to surpass around USD 9,211.73 million by 2030, poised to grow at a CAGR of 10.13% from 2022 to 2030.
-Market-Size-2021-to-2030.jpg "Human Growth Hormone (hGH) Market Size 2021 to 2030")
Key Findings Of The Study
The human growth hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland that regulates cell growth, cell regeneration and repair, reproduction, and metabolism that contributes to complete human growth. Growth hormone levels in the human body should be suitable for normal growth and can be controlled by factors such as exercise, sleep, stress, and low glucose levels. Human growth hormones also help regulate body composition, muscle growth & bone growth, body fluids, sugar & fat metabolism, and recovery from injury. It also helps increase muscle strength and performance.
In humans, a deficiency of growth hormone is caused when the pituitary gland does not include adequate concentration of human growth hormone. This deficiency is treated by injecting human growth hormone with a subcutaneous injection. Various genetic disorders such as Prader-Willi syndrome and Turner syndrome can also cause growth hormone deficiency, resulting in delayed puberty and shorter height than averages.
Turner syndrome, also known as congenital ovarian hypoplasia syndrome, occurs when the X chromosome is partially or completely lost in women. Turner syndrome (TS) is the most common type of human chromosomal aberration that occurs at 1:2,500 live births.
Human growth hormone helps promote regeneration, reproduction, and growth. Increased use of growth hormone and growth hormone awareness, which helps in the management of hormonal imbalance disorders, enhances the market growth.
In addition, many companies are investing in R&D to develop a growth hormone that has fewer side effects and will be a long-term treatment. The growth in the market is due to the increase in diseases related to growth hormone deficiency, rise in use of aging hormones, efforts taken by governments and various private organizations to spread awareness of growth hormone deficiency, and strong productivity. Other factors such as increased awareness of the treatment process, increased number of health disorders, and increased neuropsychiatric cases are projected to improve the growth of the human growth hormone market. The rapid growth of new human growth hormone novels is expected to drive the human growth hormone market growth.
The COVID-19 outbreak is anticipated to impact the global human growth hormone market. As per an article from Frontiers, the patients with decreased growth hormone secretion present a risk factor for COVID-19, which requires attention that will help in the prevention of COVID-19. Along with this, patients who are suffering from Prader-Willi syndrome also need to take enough care to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not show typical symptoms such as a high temperature and they may also experience a higher-than-normal pain threshold which may delay in the diagnosis of COVID-19. Individuals with Turner syndrome are at higher risk for severe illness from the COVID-19 virus. The COVID-19 pandemic has stressed and impacted the healthcare systems of the world. The lockdown situation all over the world, has created obstacles for both the patients and the healthcare providers.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 3,865.4 million |
| Revenue Forecast by 2030 | USD 9,211.73 million |
| Growth rate from 2022 to 2030 | CAGR of 10.13% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Application, Route of Administration, Distribution Channel |
| Companies Covered | Novo Nordisk; Merck & Co.; Eli Lilly And Company; Pfizer Inc.; TEVA PHARMACEUTICAL INDUSTRIES.; Novartis AG; Anhui Anke Biotechnology (Group) Co., Ltd.; Roche; Ipsen; Ferring BV; |
Human Growth Hormone Market Segmentation
The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is divided into Growth hormone deficiency, Prader-willi syndrome, Turner syndrome, Small for gestational age (SGA), and Others. On the basis of route of administration, the market is divided into oral, intravenous, intramuscular, and subcutaneous. On the basis of distribution channel, the market is fragmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Segment review
On the basis of application, the human growth hormone market is divided into growth hormone deficiency, Prader Willi syndrome, Turner syndrome, small for gestational age, idiopathic short stature, and others. The Turner syndrome segment held a major share in the human growth hormone market in 2020 and is expected to continue the trend during the forecast period. This is attributed to the increase in incidence of Turner syndrome across the globe. Further, this syndrome affects 1 female in 2,000 to 2,500 live female births,
On the basis of administration, the market is categorized into oral, intravenous, subcutaneous, and intramuscular. The subcutaneous route of administration segment held a major share in the human growth hormone market in 2020 and is expected to continue the trend during the forecast period. This is attributed to the fact that when injected subcutaneously, the hormone is majorly absorbed in the cells, which is beneficial for the patients.
On the basis of distribution channel, the market is segregated into hospital pharmacy, retail pharmacy, clinics, and online pharmacy. The hospital pharmacy segment dominated the global human growth hormone market in 2020 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the preference and ease of availability of artificial or recombinant human growth hormone in hospital pharmacies.
Region segment review
Region-wise, North America dominated the market in 2020, owing to the factors like rise in geriatric population, presence of many market giants, and new research to develop innovative recombinant human growth hormone. However, Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period, owing to the increase in population and rise in awareness amongst the population. Along with this, there has been progress in the economic situation of the continent and growth in healthcare infrastructure.
Prominent players in the market report include Novo Nordisk, Merck & Co., Eli Lilly & Company, Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd., Roche, Ipsen, and Ferring BV.
Key Players
Market Segments
By Application
By Route of Administration
By Distribution Channel
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Human Growth Hormone (hGH) Market
5.1. COVID-19 Landscape: Human Growth Hormone (hGH) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Human Growth Hormone (hGH) Market, By Application
8.1. Human Growth Hormone (hGH) Market, by Application, 2022-2030
8.1.1 Growth hormone deficiency
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Prader-Willi syndrome
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Turner syndrome
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Small for gestational age (SGA)
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Human Growth Hormone (hGH) Market, By Route of Administration
9.1. Human Growth Hormone (hGH) Market, by Route of Administration, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Intravenous
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Intramuscular
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Subcutaneous
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Human Growth Hormone (hGH) Market, By Distribution Channel
10.1. Human Growth Hormone (hGH) Market, by Distribution Channel, 2022-2030
10.1.1. Hospital pharmacy
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail pharmacy
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Human Growth Hormone (hGH) Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Novo Nordisk
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck & Co.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly And Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. TEVA PHARMACEUTICAL INDUSTRIES.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Anhui Anke Biotechnology (Group) Co., Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Roche
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ipsen
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Ferring BV
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers